|
Intent-to-treat population
|
352
|
352
|
248
|
247
|
|
Age, median (range), yr
|
55(18–91)
|
54(18–88)
|
55(25–85)
|
56(23–88)
|
|
Male sex, no. (%)
|
208(59)
|
180(51)
|
140(56)
|
146(59)
|
|
ECOG score, no./total no. (%)
|
|
0
|
248/350(71)
|
248/352(70)
|
164/244(67)
|
184/243(76)
|
|
1
|
102/350(29)
|
14/352(30)
|
80/244(33)
|
58/243(24)
|
|
2
|
0/350
|
0/352
|
0/244
|
1/243(<1)
|
|
Metastatic status, no./total no. (%)
|
|
M0
|
14/351(4)
|
26/351(7)
|
13(5)
|
21(9)
|
|
M1a
|
55/351(16)
|
50/351(14)
|
40(16)
|
40(16)
|
|
M1b
|
61/351(17)
|
67/351(19)
|
42(17)
|
40(16)
|
|
M1c
|
221/351(63)
|
208/351(59)
|
153(62)
|
146(59)
|
|
Elevated LDH, no. /total no. (%)
|
118/351(34)
|
114/352(32)
|
104/242(43)
|
112/242(46)
|
|
BRAF mutation, no. /total no. (%)
|
|
V600E
|
312/346(90)
|
317/351(90)
|
174/206(84)
|
170/194(88)
|
|
V600K
|
34/346(10)
|
34 /351(10)
|
32/206(16)
|
24/194(12)
|
